AzurRx BioPharma Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AzurRx BioPharma stock.
View analyst ratings for AzurRx BioPharma or view top-rated stocks.

Wall Street analysts have given AzurRx BioPharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AzurRx BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

AzurRx BioPharma saw a increase in short interest in January. As of January 29th, there was short interest totaling 2,530,000 shares, an increase of 169.8% from the January 14th total of 937,900 shares. Based on an average daily trading volume, of 6,870,000 shares, the short-interest ratio is currently 0.4 days.
View AzurRx BioPharma's Short Interest.

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for AzurRx BioPharma.

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AZRX shares have increased by 96.7% and is now trading at $1.21.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 1 year target prices for AzurRx BioPharma's shares. Their forecasts range from $3.00 to $3.50. On average, they anticipate AzurRx BioPharma's stock price to reach $3.25 in the next year. This suggests a possible upside of 168.6% from the stock's current price.
View analysts' price targets for AzurRx BioPharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to AzurRx BioPharma include ANI Pharmaceuticals (ANIP), CytomX Therapeutics (CTMX), Verrica Pharmaceuticals (VRCA), Nature's Sunshine Products (NATR), Aeglea BioTherapeutics (AGLE), Forte Biosciences (FBRX), VYNE Therapeutics (VYNE), Graybug Vision (GRAY), Tonix Pharmaceuticals (TNXP), Trevena (TRVN), RedHill Biopharma (RDHL), Paratek Pharmaceuticals (PRTK), Oncorus (ONCR), Immunic (IMUX) and CymaBay Therapeutics (CBAY).
View all of AZRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

AzurRx BioPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.23%), Renaissance Technologies LLC (0.25%) and Parsons Capital Management Inc. RI (0.48%).
View institutional ownership trends for AzurRx BioPharma.

AZRX stock was sold by a variety of institutional investors in the last quarter, including Parsons Capital Management Inc. RI.
View insider buying and selling activity for AzurRx BioPharma or view top insider-selling stocks.

AZRX stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Renaissance Technologies LLC.
View insider buying and selling activity for AzurRx BioPharma or or view top insider-buying stocks.

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AZRX stock can currently be purchased for approximately $1.21.

AzurRx BioPharma has a market capitalization of $91.42 million.

AzurRx BioPharma employs 10 workers across the globe.

The official website for AzurRx BioPharma is www.azurrx.com.

AzurRx BioPharma is headquartered at 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226.

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]